<DOC>
	<DOCNO>NCT00733746</DOCNO>
	<brief_summary>PURPOSE : This phase II trial study well gemcitabine erlotinib work give surgery treat patient pancreatic cancer remove surgery . Drugs use chemotherapy , gemcitabine , work different way stop growth tumor cell , either kill cell stop dividing . Erlotinib may stop growth tumor cell block enzymes need cell growth . Giving gemcitabine erlotinib surgery may make tumor small reduce amount normal tissue need remove . Giving drug surgery may kill tumor cell remain surgery .</brief_summary>
	<brief_title>Gemcitabine Erlotinib Before After Surgery Treating Patients With Pancreatic Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>This single arm , non-randomized phase II study . Eligible , fully registered patient receive preoperative chemotherapy consist gemcitabine plus erlotinib . Preoperative chemotherapy follow exploratory laparotomy pancreaticoduodenectomy . Patients receive postoperative chemotherapy consist gemcitabine plus erlotinib . Up 123 patient accrue study , expectation 78 patient remain fully eligible evaluable primary endpoint . The primary secondary objective study list . Primary Objective : To estimate proportion patient alive two year date registration Secondary Objectives : 1 . To determine resection rate ( define fraction patient proceed plan surgery removal primary tumor [ R0/R1 ] ) follow induction treatment gemcitabine plus erlotinib 2 . To estimate time disease progression/relapse 3 . To evaluate rate R0 , R1 , R2 resection ( define per 6th edition AJCC Cancer Staging Manual ) patient treat preoperative gemcitabine plus erlotinib chemotherapy 4 . To evaluate toxicity profile preoperative gemcitabine plus erlotinib feasibility postoperative gemcitabine plus erlotinib 5 . To evaluate response rate preoperative chemotherapy patient treat preoperative gemcitabine erlotinib 6 . To identify molecular predictor pancreatic cancer response gemcitabine combine erlotinib 7 . To identify genetic profile pancreatic adenocarcinoma may associate response neoadjuvant therapy After completion postoperative chemotherapy treatment , patient follow every 3 month 2 year every 6 month 2 year .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Eligibility Criteria : 1 . Cytologic histologic proof adenocarcinoma pancreatic head uncinate process . NOTE : Patients tumor pancreatic neck , body tail eligible . Patients evidence neuroendocrine tumor , duodenal adenocarcinoma , ampullary adenocarcinoma eligible . 2 . Localized , potentially resectable tumor define . All patient must stag chest Xray CT , abdominal CT ( contrastenhanced , helical thincut ) MRI . Radiological resectability define follow criterion abdominal imaging : No evidence tumor extension celiac axis , hepatic artery , superior mesenteric artery No evidence tumor encasement occlusion superior mesenteric vein ( SMV ) SMV/portal vein confluence No evidence visceral peritoneal metastasis NOTE : Patients borderline resectable marginally resectable pancreatic cancer eligible . Patients must meet objective image criterion outline . 3 . ≥ 18 year age 4 . ECOG/Zubrod performance status 0 1 5 . Baseline weight loss ≤ 15 % premorbid weight 6 . Patient must adequate hematologic , renal , hepatic function define : WBC ≥ 2,000 cells/mm³ ANC ≥ 1,500 cells/mm³ Platelets ≥ 100,000 cells/mm³ Serum bilirubin ≤ 2.5 mg/dL Serum creatinine ≤ 1.5 mg/dL calculate creatinine clearance ≥ 50 ml/min ( 24 hour urine collection ) ALT &lt; 2.5 time upper limit normal ( ULN ) AST &lt; 2.5 time ULN Albumin ≥ 3.2 g/dl 7 . No history follow : Prior EGFR target therapy therapy pancreatic cancer Active infection require intravenous antibiotic time registration 8 . Nonpregnant nonbreast feeding . Female participant child bear potential must negative urine serum pregnancy test prior registration . Perimenopausal participant must amenorrheic ≥ 12 month consider childbearing potential . All patient reproductive potential must agree use effective method birth control receive study therapy . 9 . No prior malignancy within 5 year registration ( Exceptions : nonmelanoma skin cancer , insitu cancer )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage I pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
</DOC>